The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM

Citation
Lj. Vleming et al., The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM, CLIN NEPHR, 51(3), 1999, pp. 133-140
Citations number
43
Categorie Soggetti
Urology & Nephrology","da verificare
Journal title
CLINICAL NEPHROLOGY
ISSN journal
03010430 → ACNP
Volume
51
Issue
3
Year of publication
1999
Pages
133 - 140
Database
ISI
SICI code
0301-0430(199903)51:3<133:TDGOTA>2.0.ZU;2-G
Abstract
Background: The insertion-deletion (I/D) polymorphism of the angiotensin co nverting enzyme gene is a diallelic polymorphism that constitutes a genetic influence on the progression of renal diseases such as IgA nephropathy. Pa tients with the DD genotype have an accelerated progression towards end sta ge renal failure in these diseases. The role of the I/D polymorphism in the pathogenesis of diabetic nephropathy in IDDM is unresolved. Patients and m ethods: We therefore set out to study the contribution of the I/D polymorph ism in 79 patients (age 39.5 +/- 7.6 years (mean +/- SD) with end stage ren al failure due to diabetic nephropathy, who were recipients of a combined k idney-pancreas transplantation (n = 60), or who were on the waiting list fo r such a procedure (n = 19). The control series consisted of 82 patients (a ge 39.5 +/- 9.6 years) without microalbuminuria after fifteen years of IDDM . Results: The ACE genotype distribution in patients was not in accordance with the Hardy-Weinberg equilibrium due to a significant overrepresentation of the DD genotype (X-2 = 8.9, p = 0.01). This resulted in a significant i ncrease of the D-allele frequency in the cases compared to controls (X-2 = 4.9, p = 0.03). The presence of one D-allele did not increase the risk of e nd stage renal failure (odds ratio ID/II = 1.0, 95% Cl 0.4 - 2.2). The pres ence of the DD genotype increased the risk of end stage renal failure twofo ld compared to the other genotypes (odds ratio 2.1, 95% Cl 1.1 - 4.0). The risk estimate seemed slightly higher in patients with good metabolic contro l (odds ratio 2.6, 95% Cl 1.0 - 7.1), than in patients with poor control (o dds ratio 1.6, 95% Cl 0.59 - 4.3). Conclusion: It is concluded that the ris k of end-stage renal failure in patients with IDDM is twofold increased in patients with the DD genotype as compared to patients with other genotypes.